Bio€quity Europe— May 12-14, 2023 – Dublin, Ireland
![](https://exevir.com/wp-content/uploads/2023/03/Bioequity2023-1024x576.jpg)
Excited to be a part of the Presenting Company Class of 2023 at BioEquity: Europe 2023!
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
![](https://exevir.com/wp-content/uploads/2023/03/IC-1024x640.png)
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike
Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
![](https://exevir.com/wp-content/uploads/2023/01/Picture_ExeVir_EIB.jpg)
xeVir Bio, a biotech company developing robust nanobody therapies for broad protection against infectious diseases, today announced that it has secured a venture debt financing agreement of up to EUR 25M (around USD 26.5m) with the European Investment Bank (EIB)*. The EIB financing will help advance ExeVir’s lead asset, XVR012, into clinical trials for COVID-19.
Bio Partnering at JPM — January 9-12, 2023 – San Francisco, CA
![](https://exevir.com/wp-content/uploads/2023/01/BioPartnering@JPM.png)
ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit from vaccines, such as immunocompromised individuals. The versatile VHH platform enables both prevention and treatment of bacterial and viral threats.